Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Rating of “Buy” from Brokerages

Zealand Pharma A/S (OTCMKTS:ZLDPF) has earned a consensus recommendation of “Buy” from the eight research firms that are covering the stock, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold recommendation and four have issued a strong buy recommendation on the company.

ZLDPF has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Zealand Pharma A/S in a research report on Tuesday, December 16th. William Blair reiterated a “market perform” rating on shares of Zealand Pharma A/S in a report on Friday. BTIG Research upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Friday, November 28th. Finally, Cantor Fitzgerald restated a “neutral” rating on shares of Zealand Pharma A/S in a research report on Friday.

Zealand Pharma A/S Stock Performance

Shares of ZLDPF stock opened at $39.95 on Friday. The company has a current ratio of 14.10, a quick ratio of 14.10 and a debt-to-equity ratio of 0.02. The stock has a 50 day simple moving average of $64.22 and a 200-day simple moving average of $70.69. The company has a market cap of $2.84 billion, a price-to-earnings ratio of 2.92 and a beta of 0.75. Zealand Pharma A/S has a 12-month low of $35.93 and a 12-month high of $101.29.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its quarterly earnings results on Thursday, February 19th. The company reported ($0.81) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.34) by $0.53. The firm had revenue of $10.79 million for the quarter, compared to the consensus estimate of $19.69 million. Zealand Pharma A/S had a return on equity of 49.76% and a net margin of 70.06%. On average, equities analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.

More Zealand Pharma A/S News

Here are the key news stories impacting Zealand Pharma A/S this week:

• Positive Sentiment: Roche and Zealand reported the midstage (Phase 2) trial met its prespecified goal and highlighted tolerability, saying the data support further development of petrelintide for chronic weight management (either alone or in combination). Roche, Zealand Pharma Obesity Drug Hits Goal in Midstage Trial
• Positive Sentiment: Zealand’s own releases and coverage from business outlets framed the Phase 2 readout as positive for petrelintide, emphasizing potential to advance the program and the drug’s amylin-analog mechanism as a differentiated approach in weight management. Zealand Pharma announces positive Phase 2 results for petrelintide
• Positive Sentiment: Industry press also described the Roche/Zealand collaboration as achieving a successful midstage readout, supporting continued development of the program. Roche succeeds in mid-stage trial for obesity drug developed with Zealand
• Neutral Sentiment: William Blair reaffirmed a “market perform” rating on Zealand, leaving guidance unchanged — a sign analysts are holding a wait‑and‑see stance rather than turning bullish. (Current quoted price cited in analyst notes: $39.95.)
• Neutral Sentiment: Cantor Fitzgerald likewise reaffirmed a “neutral” rating, indicating no immediate upgrades from these sell‑side firms despite the trial news. (Current quoted price cited in analyst notes: $39.95.)
• Negative Sentiment: MarketWatch reported that the trial’s weight‑loss results were disappointing relative to market expectations, and that focus on the magnitude of weight loss (rather than tolerability or hit/miss of a specific statistical endpoint) spurred the selloff. Disappointing weight-loss-trial results from Zealand Pharma sends shares tumbling
• Negative Sentiment: MSN summarized investor disappointment over the weight‑loss magnitude in the Phase 2 readout and noted the sharp share decline as traders punished the perceived shortfall versus expectations. This Danish biotech’s new weight-loss drug disappointed investors, and its stock is tumbling

Zealand Pharma A/S Company Profile

Zealand Pharma A/S is a Denmark‐based biopharmaceutical company specializing in the discovery, design and development of peptide‐based therapeutics. Utilizing proprietary peptide engineering platforms, the company focuses on metabolic and endocrine disorders, including diabetes and rare gastrointestinal diseases. Zealand employs a rational design approach to optimize stability, selectivity and dosing profiles of its candidates, aiming to improve patient outcomes where current treatment options are limited.

Among the most advanced assets in Zealand’s pipeline is dasiglucagon, a stable glucagon analog designed for the emergency treatment of severe hypoglycemia.